Who has access to the TYA Advisory Group?
Clinicians with expertise in TYA-relevant cancers (e.g. sarcomas, CNS, melanoma, germ cell, haematology); representatives with paediatric-trials portfolio expertise.
How does it work?
A Microsoft Teams channel where group members discuss complex TYA patient cases and obtain feedback and recommendations from the wider group.
Why is the tool not open to patients and public?
The TYA Advisory Group is for clinical staff only. Any patient data is pseudonymised and contains no patient identifiers. Medical terminology used assumes clinical expertise.
Who is leading this project?
The ECMC Programme Office is delivering the project on behalf of the ECMC network.
Who is in the ECMC network?
The Experimental Cancer Medicine Centre (ECMC) network includes world-leading scientists and clinicians driving the discovery, development and testing of new cancer treatments. Centres are jointly funded by Cancer Research UK, the Little Princess Trust, the National Institute for Health and Care Research (England) and the Departments of Health for Scotland, Wales and Northern Ireland.
Is there any commercial involvement?
The project is led by the ECMC network and Cancer Research UK. There is no commercial involvement.
What information is included in the TYA Trials Advisory Group case discussion form?
The information requested can be found on the TYA Trials Advisory Group case form.
No patient identifiable information is provided or shared as part of this process.
Still have questions?
Please get in touch: ecmcadmin@cancer.org.uk